new systemic drugs extend overall survival for mCRPC by 6 months.

[George71]

Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry.

ncbi.nlm.nih.gov/pubmed/306...

[NPfisherman]

This study was looking between 2010-2014 and earlier times, but the following line says a lot--

Although the median survival was only modestly improved and less than predicted when simply adding each newer drug survival advantage, the cumulative benefit from the new therapies was more pronounced in longer-term survivors and de-novo patients.

The Stage 4 survival rate for 5 years is listed at 30%--using data from 2010 to 2014--abiraterone was approved December, 2012...The reality is that when the numbers are updated again, it will likely be above 50%, and this continues to improve as drug regimens are changed based on Stampede and other trials, and as new drugs are added... when my wife and I first read that, we freaked out... after meeting with my MO, and he said my OS was 5-10 years, who knows?? New discoveries are made every week... we felt better...

I exercise daily, lift weights 3-5 x per week, changed diet, lost weight, added supplements.. We are all in a war...choose how you fight....the other day, TWTJr posted he had been fighting 19 years...had multiple bone lesions (>6 I believe) treated 6 years ago with radiation.... he was way ahead of SABR-COMET....There are no guarantees and everyone's cancer is different...

May we all choose well in our fight....

Fish